original ) (raw )Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
Federico Navarro-sarabia
Annals of the Rheumatic Diseases, 2013
View PDFchevron_right
Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study
Federico Navarro-sarabia
Clinical and experimental rheumatology, 2018
View PDFchevron_right
Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial
Ricardo Blanco
Annals of the rheumatic diseases, 2017
View PDFchevron_right
Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)
Yoshiya Tanaka
Annals of the rheumatic diseases, 2016
View PDFchevron_right
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
Mark Genovese
Annals of the Rheumatic Diseases, 2010
View PDFchevron_right
Tocilizumab as a first-line biologic treatment in rheumatoid arthritis patients – the impact of concomitant methotrexate treatment and Rheumatic Disease Comorbidity Index on the clinical response – results from the multicenter observational ACT-POL study
Sławomir Jeka
Rheumatology
View PDFchevron_right
Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study
Isabelle Idier
Rheumatology and Therapy, 2020
View PDFchevron_right
Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
Dimitrios Pappas
Rheumatology and Therapy, 2020
View PDFchevron_right
Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
Joel Kremer
Rheumatology and Therapy
View PDFchevron_right
Comparative Effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the Treatment of Rheumatoid Arthritis
M Victoria Hernandez
PLOS ONE, 2015
View PDFchevron_right
Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study
Isabelle Idier
RMD Open, 2017
View PDFchevron_right
Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index
Kiyoshi Aoyagi
Modern Rheumatology, 2011
View PDFchevron_right
A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period
Yoshiya Tanaka
Modern rheumatology, 2017
View PDFchevron_right
Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study
Alejandro alvarez
Annals of the Rheumatic Diseases, 2011
View PDFchevron_right
Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study
Yoshiya Tanaka
Modern rheumatology / the Japan Rheumatism Association, 2016
View PDFchevron_right
Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
O. Troum
View PDFchevron_right
Clinical Factors and the Outcome of Treatment with Methotrexate in Rheumatoid Arthritis: Role of Rheumatoid Factor, Erosive Disease and High Level of Erythrocyte Sedimentation Rate
Piotr Kusnierczyk
Journal of Clinical Medicine
View PDFchevron_right
A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
L. Rowell
Annals of the Rheumatic Diseases, 2014
View PDFchevron_right
Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice
Maher Aassi
Clinical rheumatology, 2015
View PDFchevron_right
Efficacy and safety of tocilizumab in refractory rheumatoid arthritis: a real life cohort from a single centre
Pierluigi Macchioni
Clinical and experimental rheumatology
View PDFchevron_right
Sustained Clinical Remission and Rate of Relapse After Tocilizumab Withdrawal in Patients with Rheumatoid Arthritis
Jorge Morales Torres
The Journal of Rheumatology, 2013
View PDFchevron_right
The role of tocilizumab monotherapy in the management of rheumatoid arthritis: a review
Muhammad Aqib Nisar
International Journal of Clinical Rheumatology, 2012
View PDFchevron_right
Tofacitinib With Methotrexate in Third-Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Trial
vibeke strand
Arthritis care & research, 2015
View PDFchevron_right
Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice
Hubert Marotte
Rheumatology, 2013
View PDFchevron_right
MRI Results Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy
Joel Kremer
The Journal of Rheumatology
View PDFchevron_right
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
Irmgadt Sariego
Lancet (London, England), 2017
View PDFchevron_right
Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry
Joel Kremer
Rheumatology and Therapy, 2016
View PDFchevron_right
Tofacitinib with Methotrexate in Third-Line Treatment of Patients with Active Rheumatoid Arthritis: Patient-Reported Outcomes from a Phase 3 Trial
vibeke strand
View PDFchevron_right
Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind study
Kamilla Klama
RMD open, 2024
View PDFchevron_right
Ml28133 -A Multicenter, Open-Label, Long-Term Extension Study of WA 19926 to Describe Safety During Treatment with Tocilizumab in Patients with Early, Moderate to Severe Rheumatoid Arthritis
Filip Gucev
Macedonian Medical Review, 2017
View PDFchevron_right
Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate
Gosford Sawyerr
Rheumatology and Therapy
View PDFchevron_right
Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy
Darcy Gill
The Journal of Rheumatology, 2019
View PDFchevron_right
Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
Majed Khraishi
The Journal of Rheumatology, 2013
View PDFchevron_right